Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
Metz
Luanne
L
Department of Clinical Neurosciences, Foothills Medical Center, Alberta, T2N 2T9, Calgary, Canada. lmetz@ucalgary.ca
Page
Stacey
S
D000284:Administration, Oral; D002185:Cannabidiol / Q000008:administration & dosage / Q000627:therapeutic use; D002186:Cannabinoids / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D013759:Dronabinol / Q000008:administration & dosage / Q000627:therapeutic use; D004335:Drug and Narcotic Control; D006801:Humans; D015337:Multicenter Studies as Topic; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009128:Muscle Spasticity / Q000188:drug therapy*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014481:United States
D002186:Cannabinoids; D010919:Placebos; D002185:Cannabidiol; D013759:Dronabinol